Waters Corporation has released its financial results for Q2 2025, which exceeded analysts’ expectations. The company has also raised its full-year guidance, indicating confidence in sustained growth.
Financial Results for Q2
In Q2 2025, Waters Corporation reported sales of $771 million, representing a 9% increase compared to the same period last year. This figure surpassed the anticipated sales of $748.04 million. The growth was primarily driven by sales of instruments, including liquid chromatography and mass spectrometry technologies.
2025 Guidance
Waters Corporation has raised its full-year sales growth forecast for 2025 to the range of 5.5% to 7.5% in constant currency. Additionally, the company increased its non-GAAP EPS guidance to a range of $12.95 to $13.05, representing an approximate year-over-year growth of 9% to 10%.
Future Strategy and Plans
The company will focus on leveraging its core strengths and expanding into high-growth markets. The recent combination with BD Biosciences & Diagnostic Solutions is expected to create synergies and operational efficiencies that will significantly boost shareholder value. Integration planning is already underway.
The results and forecasts from Waters Corporation reaffirm its strong market position and strategic approach to future growth and development.
